secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xenon Pharmaceuticals Inc. (XENE)
CIK:        0001582313
Form:       8-K
Filed at:   2024-02-29T23:59:59+00:00
Accession:  0000950170-24-023080
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Xenon Pharma reports FY2023 net loss $182.4M, cash $930.9M; XEN1101 Phase 3 on track
--------------------------------------------------------------------------------

- Net loss of $44.7M in Q4 2023 and $182.4M for FY2023, vs $37.4M and $125.4M in 2022.
- R&D expenses $41.1M in Q4, $167.5M for FY2023, driven by XEN1101 Phase 3 epilepsy trials.
- Cash and marketable securities $930.9M as of Dec 31, 2023; expected runway into 2027.
- X-TOLE2 Phase 3 epilepsy patient enrollment expected to complete late 2024 to early 2025.
- End-of-Phase 2 meeting with FDA for XEN1101 in major depressive disorder planned in April 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1582313/000095017024023080/0000950170-24-023080-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1582313/000095017024023080/xene-20240229.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-023080

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer